Alterations observed in the cross-resistance experiments, best exemplified by phosphorylation of MEK1/2 in vemurafenib-resistant cells after short exposure to trametinib, also indicate remarkable plasticity of resistant melanoma cells. Here, MAP2K1 is linked to melanoma.